Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Genovese

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Journal of Magnetic Resonance Imaging : JMRI|October 27, 2004
Magnetic resonance imaging of articular cartilage of the knee: comparison between fat-suppressed three-dimensional SPGR imaging, fat-suppressed FSE imaging, and fat-suppressed three-dimensional DEFT imaging, and correlation with arthroscopyHiroshi Yoshioka, Kathryn Stevens, Brian A Hargreaves, et al.
Rheumatology and Therapy|November 16, 2017
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 StudyHasan Tahir, Atul Deodhar, Mark Genovese, et al.
Arthritis Research & Therapy|November 19, 2010
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD studySudha Visvanathan, Mahboob U Rahman, Edward Keystone, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|December 11, 2002
COX-2 selective NSAID decreases bone ingrowth in vivoStuart Goodman, Ting Ma, Michael Trindade, et al.
Arthritis and Rheumatism|December 1, 2007
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trialMaria Dall'Era, Eliza Chakravarty, Daniel Wallace, et al.
Arthritis Research & Therapy|May 19, 2015
Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapyNitya Nair, Henrik E Mei, Shih-Yu Chen, et al.
RMD Open|December 31, 2020
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathyMatthew Baker, Yashaar Chaichian, Mark Genovese, et al.
Annals of the Rheumatic Diseases|August 4, 2021
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III studyEvgeniy Nasonov, Saeed Fatenejad, Eugen Feist, et al.
Arthritis Care & Research|August 27, 2016
Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality MeasuresJinoos Yazdany, Mark Robbins, Gabriela Schmajuk, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of Magnetic Resonance Imaging : JMRI|October 27, 2004
Magnetic resonance imaging of articular cartilage of the knee: comparison between fat-suppressed three-dimensional SPGR imaging, fat-suppressed FSE imaging, and fat-suppressed three-dimensional DEFT imaging, and correlation with arthroscopyHiroshi Yoshioka, Kathryn Stevens, Brian A Hargreaves, et al.
Rheumatology and Therapy|November 16, 2017
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 StudyHasan Tahir, Atul Deodhar, Mark Genovese, et al.
Arthritis Research & Therapy|November 19, 2010
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD studySudha Visvanathan, Mahboob U Rahman, Edward Keystone, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|December 11, 2002
COX-2 selective NSAID decreases bone ingrowth in vivoStuart Goodman, Ting Ma, Michael Trindade, et al.
Arthritis and Rheumatism|December 1, 2007
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trialMaria Dall'Era, Eliza Chakravarty, Daniel Wallace, et al.
Arthritis Research & Therapy|May 19, 2015
Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapyNitya Nair, Henrik E Mei, Shih-Yu Chen, et al.
RMD Open|December 31, 2020
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathyMatthew Baker, Yashaar Chaichian, Mark Genovese, et al.
Annals of the Rheumatic Diseases|August 4, 2021
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III studyEvgeniy Nasonov, Saeed Fatenejad, Eugen Feist, et al.
Arthritis Care & Research|August 27, 2016
Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality MeasuresJinoos Yazdany, Mark Robbins, Gabriela Schmajuk, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
Pageof 4